Biologics and BiosimilarsSouth America Market Size, Industry Trends, and Statistics Report

Biologics and Biosimilars-South America Market Status and Trend Report 2013-2023

Report ID: MIReports 7234 | Number of pages: 147 | Publish Date: Jun 2019 | Category: Lifesciences and Healthcare
Report Summary

Biologics and Biosimilars-South America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole South America and Regional Market Size of Biologics and Biosimilars 2013-2017, and development forecast 2018-2023
Main market players of Biologics and Biosimilars in South America, with company and product introduction, position in the Biologics and Biosimilars market
Market status and development trend of Biologics and Biosimilars by types and applications
Cost and profit status of Biologics and Biosimilars, and marketing status
Market growth drivers and challenges

The report segments the South America Biologics and Biosimilars market as:

South America Biologics and Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Brazil
Argentina
Venezuela
Colombia
Others

South America Biologics and Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody 
Hormone 
Growth Factors 
Other

South America Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor 
Diabetes 
Cardiovascular 
Hemophilia 
Other

South America Biologics and Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche 
Amgen 
AbbVie 
Sanofi-Aventis 
Johnson & Johnson 
Pfizer 
Novo Nordisk 
Eli Lilly 
Novartis 
Merck 
3sbio 
Changchun High Tech 
CP Guojian 
Biotech 
Gelgen 
Innovent 
Dong Bao 
Ganlee 
United Laboratories 

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Interested in this report?
Get your sample now!
Table of Contents
Chapter 1 Overview of Biologics and Biosimilars
    1.1 Definition of Biologics and Biosimilars in This Report
    1.2 Commercial Types of Biologics and Biosimilars
        1.2.1 Antibody 
        1.2.2 Hormone 
        1.2.3 Growth Factors 
        1.2.4 Other
    1.3 Downstream Application of Biologics and Biosimilars
        1.3.1 Tumor 
        1.3.2 Diabetes 
        1.3.3 Cardiovascular 
        1.3.4 Hemophilia 
        1.3.5 Other
    1.4 Development History of Biologics and Biosimilars
    1.5 Market Status and Trend of Biologics and Biosimilars 2013-2023
        1.5.1 South America Biologics and Biosimilars Market Status and Trend 2013-2023
        1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2013-2023
Chapter 2 South America Market Status and Forecast by Regions
    2.1 Market Status of Biologics and Biosimilars in South America 2013-2017
    2.2 Consumption Market of Biologics and Biosimilars in South America by Regions
        2.2.1 Consumption Volume of Biologics and Biosimilars in South America by Regions
        2.2.2 Revenue of Biologics and Biosimilars in South America by Regions
    2.3 Market Analysis of Biologics and Biosimilars in South America by Regions
        2.3.1 Market Analysis of Biologics and Biosimilars in Brazil 2013-2017
        2.3.2 Market Analysis of Biologics and Biosimilars in Argentina 2013-2017
        2.3.3 Market Analysis of Biologics and Biosimilars in Venezuela 2013-2017
        2.3.4 Market Analysis of Biologics and Biosimilars in Colombia 2013-2017
        2.3.5 Market Analysis of Biologics and Biosimilars in Others 2013-2017
    2.4 Market Development Forecast of Biologics and Biosimilars in South America 2018-2023
        2.4.1 Market Development Forecast of Biologics and Biosimilars in South America 2018-2023
        2.4.2 Market Development Forecast of Biologics and Biosimilars by Regions 2018-2023
Chapter 3 South America Market Status and Forecast by Types
    3.1 Whole South America Market Status by Types
        3.1.1 Consumption Volume of Biologics and Biosimilars in South America by Types
        3.1.2 Revenue of Biologics and Biosimilars in South America by Types
    3.2 South America Market Status by Types in Major Countries
        3.2.1 Market Status by Types in Brazil
        3.2.2 Market Status by Types in Argentina
        3.2.3 Market Status by Types in Venezuela
        3.2.4 Market Status by Types in Colombia
        3.2.5 Market Status by Types in Others
    3.3 Market Forecast of Biologics and Biosimilars in South America by Types
Chapter 4 South America Market Status and Forecast by Downstream Industry
    4.1 Demand Volume of Biologics and Biosimilars in South America by Downstream Industry
    4.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Major Countries
        4.2.1 Demand Volume of Biologics and Biosimilars by Downstream Industry in Brazil
        4.2.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Argentina
        4.2.3 Demand Volume of Biologics and Biosimilars by Downstream Industry in Venezuela
        4.2.4 Demand Volume of Biologics and Biosimilars by Downstream Industry in Colombia
        4.2.5 Demand Volume of Biologics and Biosimilars by Downstream Industry in Others
    4.3 Market Forecast of Biologics and Biosimilars in South America by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Biologics and Biosimilars
    5.1 South America Economy Situation and Trend Overview
    5.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview
Chapter 6 Biologics and Biosimilars Market Competition Status by Major Players in South America
    6.1 Sales Volume of Biologics and Biosimilars in South America by Major Players
    6.2 Revenue of Biologics and Biosimilars in South America by Major Players
    6.3 Basic Information of Biologics and Biosimilars by Major Players
        6.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Players
        6.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Players
    6.4 Market Competition News and Trend
        6.4.1 Merger, Consolidation or Acquisition News
        6.4.2 Investment or Disinvestment News
        6.4.3 New Product Development and Launch
Chapter 7 Biologics and Biosimilars Major Manufacturers Introduction and Market Data
    7.1 Roche 
        7.1.1 Company profile
        7.1.2 Representative Biologics and Biosimilars Product
        7.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche 
    7.2 Amgen 
        7.2.1 Company profile
        7.2.2 Representative Biologics and Biosimilars Product
        7.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen 
    7.3 AbbVie 
        7.3.1 Company profile
        7.3.2 Representative Biologics and Biosimilars Product
        7.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie 
    7.4 Sanofi-Aventis 
        7.4.1 Company profile
        7.4.2 Representative Biologics and Biosimilars Product
        7.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis 
    7.5 Johnson & Johnson 
        7.5.1 Company profile
        7.5.2 Representative Biologics and Biosimilars Product
        7.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson 
    7.6 Pfizer 
        7.6.1 Company profile
        7.6.2 Representative Biologics and Biosimilars Product
        7.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer 
    7.7 Novo Nordisk 
        7.7.1 Company profile
        7.7.2 Representative Biologics and Biosimilars Product
        7.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk 
    7.8 Eli Lilly 
        7.8.1 Company profile
        7.8.2 Representative Biologics and Biosimilars Product
        7.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly 
    7.9 Novartis 
        7.9.1 Company profile
        7.9.2 Representative Biologics and Biosimilars Product
        7.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis 
    7.10 Merck 
        7.10.1 Company profile
        7.10.2 Representative Biologics and Biosimilars Product
        7.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck 
    7.11 3sbio 
        7.11.1 Company profile
        7.11.2 Representative Biologics and Biosimilars Product
        7.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio 
    7.12 Changchun High Tech 
        7.12.1 Company profile
        7.12.2 Representative Biologics and Biosimilars Product
        7.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech 
    7.13 CP Guojian 
        7.13.1 Company profile
        7.13.2 Representative Biologics and Biosimilars Product
        7.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian 
    7.14 Biotech 
        7.14.1 Company profile
        7.14.2 Representative Biologics and Biosimilars Product
        7.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech 
    7.15 Gelgen 
        7.15.1 Company profile
        7.15.2 Representative Biologics and Biosimilars Product
        7.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen 
    7.16 Innovent 
    7.17 Dong Bao 
    7.18 Ganlee 
    7.19 United Laboratories 
Chapter 8 Upstream and Downstream Market Analysis of Biologics and Biosimilars
    8.1 Industry Chain of Biologics and Biosimilars
    8.2 Upstream Market and Representative Companies Analysis
    8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Biologics and Biosimilars
    9.1 Cost Structure Analysis of Biologics and Biosimilars
    9.2 Raw Materials Cost Analysis of Biologics and Biosimilars
    9.3 Labor Cost Analysis of Biologics and Biosimilars
    9.4 Manufacturing Expenses Analysis of Biologics and Biosimilars
Chapter 10 Marketing Status Analysis of Biologics and Biosimilars
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Reference

List of Tables

    Table Advantage and Disadvantage of Antibody 
    Table Advantage and Disadvantage of Hormone 
    Table Advantage and Disadvantage of Growth Factors 
    Table Advantage and Disadvantage of Other
    Table Consumption Volume of Biologics and Biosimilars in South America by Regions 2013-2017
    Table Revenue of Biologics and Biosimilars in South America by Regions 2013-2017
    Table Consumption Volume of Biologics and Biosimilars in South America by Regions 2018-2023
    Table Revenue of Biologics and Biosimilars in South America by Regions 2018-2023
    Table Consumption Volume of Biologics and Biosimilars in South America by Types 2013-2017
    Table Revenue of Biologics and Biosimilars in South America by Types 2013-2017
    Table Consumption Volume of Biologics and Biosimilars by Types in Brazil 2013-2017
    Table Consumption Volume of Biologics and Biosimilars by Types in Argentina 2013-2017
    Table Consumption Volume of Biologics and Biosimilars by Types in Venezuela 2013-2017
    Table Consumption Volume of Biologics and Biosimilars by Types in Colombia 2013-2017
    Table Consumption Volume of Biologics and Biosimilars by Types in Others 2013-2017
    Table Consumption Volume Forecast of Biologics and Biosimilars in South America by Types 2018-2023
    Table Revenue Forecast of Biologics and Biosimilars in South America by Types 2018-2023
    Table Demand Volume of Biologics and Biosimilars in South America by Downstream Industry 2013-2017
    Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Brazil 2013-2017
    Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Argentina 2013-2017
    Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Venezuela 2013-2017
    Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Colombia 2013-2017
    Table Demand Volume of Biologics and Biosimilars by Downstream Industry in Others 2013-2017
    Table Demand Volume Forecast of Biologics and Biosimilars in South America by Downstream Industry 2018-2023
    Table Sales Volume of Biologics and Biosimilars in South America by Major Players 2013-2017
    Table Revenue of Biologics and Biosimilars in South America by Major Players 2013-2017
    Table Headquarters Location and Established Time of Biologics and Biosimilars Major Players
    Table Employees and Revenue Level of Biologics and Biosimilars Major Players
    Table Representative Biologics and Biosimilars Product One of Roche 
    Table Representative Biologics and Biosimilars Product Two of Roche 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche  2013-2017
    Table Representative Biologics and Biosimilars Product One of Amgen 
    Table Representative Biologics and Biosimilars Product Two of Amgen 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen  2013-2017
    Table Representative Biologics and Biosimilars Product One of AbbVie 
    Table Representative Biologics and Biosimilars Product Two of AbbVie 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie  2013-2017
    Table Representative Biologics and Biosimilars Product One of Sanofi-Aventis 
    Table Representative Biologics and Biosimilars Product Two of Sanofi-Aventis 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis  2013-2017
    Table Representative Biologics and Biosimilars Product One of Johnson & Johnson 
    Table Representative Biologics and Biosimilars Product Two of Johnson & Johnson 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson  2013-2017
    Table Representative Biologics and Biosimilars Product One of Pfizer 
    Table Representative Biologics and Biosimilars Product Two of Pfizer 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer  2013-2017
    Table Representative Biologics and Biosimilars Product One of Novo Nordisk 
    Table Representative Biologics and Biosimilars Product Two of Novo Nordisk 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk  2013-2017
    Table Representative Biologics and Biosimilars Product One of Eli Lilly 
    Table Representative Biologics and Biosimilars Product Two of Eli Lilly 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly  2013-2017
    Table Representative Biologics and Biosimilars Product One of Novartis 
    Table Representative Biologics and Biosimilars Product Two of Novartis 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis  2013-2017
    Table Representative Biologics and Biosimilars Product One of Merck 
    Table Representative Biologics and Biosimilars Product Two of Merck 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck  2013-2017
    Table Representative Biologics and Biosimilars Product One of 3sbio 
    Table Representative Biologics and Biosimilars Product Two of 3sbio 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio  2013-2017
    Table Representative Biologics and Biosimilars Product One of Changchun High Tech 
    Table Representative Biologics and Biosimilars Product Two of Changchun High Tech 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech  2013-2017
    Table Representative Biologics and Biosimilars Product One of CP Guojian 
    Table Representative Biologics and Biosimilars Product Two of CP Guojian 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian  2013-2017
    Table Representative Biologics and Biosimilars Product One of Biotech 
    Table Representative Biologics and Biosimilars Product Two of Biotech 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech  2013-2017
    Table Representative Biologics and Biosimilars Product One of Gelgen 
    Table Representative Biologics and Biosimilars Product Two of Gelgen 
    Table Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen  2013-2017